

FISCAL IMPACT OF PROPOSED LEGISLATION

81st Oregon Legislative Assembly – 2022 Regular Session
Legislative Fiscal Office

Measure: HB 4081 - A

*Only Impacts on Original or Engrossed
Versions are Considered Official*

Prepared by: Michael Graham
Reviewed by: Tom MacDonald, Haylee Morse-Miller
Date: February 15, 2022

Measure Description:

Requires pharmacist who dispenses opioid prescription to offer prescription for naloxone, or similar drug, and information about naloxone under specified circumstances. Amends the definition of “kit” to include any drug approved by the United States Food and Drug Administration for the complete or partial reversal of an opioid overdose. Adds the definitions of “opioid” and “opioid overdose.” Removes a concurrent prescription of gabapentin from the list of conditions requiring a pharmacist to offer naloxone.

Government Unit(s) Affected:

Oregon Board of Pharmacy (OBOP), Oregon Health Authority (OHA)

Analysis:

This fiscal impact statement is for the purpose of transmitting the measure from the House Committee on Health Care to the Joint Committee on Ways and Means.

House Bill 4081 A-engrossed requires a pharmacist who dispenses an opioid prescription to offer a prescription for naloxone, or a similar drug, and information about naloxone under specified circumstances. The measure creates exceptions to the requirement to offer a prescription for naloxone or a similar drug. A health benefit plan must provide payment or reimbursement for a naloxone prescription and dispensation by pharmacist. The measure amends the definition of “kit” to include any drug approved by the United States Food and Drug Administration for the complete or partial reversal of an opioid overdose and adds the definitions of “opioid” and “opioid overdose.” The measure removes a concurrent prescription of gabapentin from the list of conditions requiring a pharmacist to offer naloxone. The measure takes effect 91 days after adjournment *sine die* and becomes operative on January 1, 2023.

The measure is anticipated to have an impact on the Oregon Health Authority and the Oregon Board of Pharmacy.

A more complete fiscal analysis on the measure will be prepared as the measure is considered in the Joint Committee on Ways and Means.

Further Analysis Required